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Abstract
Objective: Multiple sclerosis (MS) is a heterogenous, inflammatory disease of
the central nervous system. Microbiota alterations in MS versus healthy controls
(HC) are observed, but results are inconsistent. We studied diversity, entero-
types, and specific gut microbial taxa variation between MS and HC, and
between MS subgroups. Methods: Amplicon sequencing of the 16S ribosomal
RNA V4 region (Illumina MiSeq) was used to evaluate alpha and beta diversity,
enterotypes, and relative taxa abundances on stool samples. MS subgroups were
based on phenotype, disease course modifiers, and treatment status. Results
were controlled for recently identified confounders of microbiota composition.
Results: Ninety-eight MS patients and 120 HC were included. Microbial rich-
ness was lower in interferon-treated (RRMS_I, N = 24) and untreated relaps-
ing–remitting MS during relapse (RRMS_R, N = 4) when compared to benign
(BMS, N = 20; Z = 3.07, Pcorr = 0.032 and Z = 2.68, Pcorr = 0.055) and
primary progressive MS (PPMS, N = 26; Z = 2.39, Pcorr = 0.062 and
Z = 2.26, Pcorr = 0.071). HC (N = 120) and active untreated MS (RRMS_U,
N = 24) showed intermediate microbial richness. Enterotypes were associated
with clinical subgroups (N = 218, v2 = 36.10, P = 0.002), with Bacteroides 2
enterotype being more prevalent in RRMS_I. Butyricicoccus abundance was
lower in PPMS than in RRMS_U (Z = 3.00, Pcorr = 0.014) and BMS
(Z = 2.56, Pcorr = 0.031), lower in RRMS_I than in BMS (Z = 2.50,
Pcorr = 0.034) and RRMS_U (Z = 2.91, Pcorr = 0.013), and inversely corre-
lated with self-reported physical symptoms (rho = 0.400, Pcorr = 0.001) and
disease severity (rho = 0.223, P = 0.027). Interpretation: These results
emphasize the importance of phenotypic subcategorization in MS-microbiome
research, possibly explaining previous result heterogeneity, while showing the
potential for specific microbiome-based biomarkers for disease activity and
severity.
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Introduction
Multiple sclerosis (MS) is the most common chronic
inflammatory disease of the central nervous system
(CNS).1 Patients experience a variety of physical and cog-
nitive symptoms, including bowel dysfunction (>70%2).
Depending on relapses and/or magnetic resonance imag-
ing (MRI) activity, MS is considered active or nonactive3.
Relapses are presumably provoked by adaptive immune
cells infiltrating the CNS, resulting in focal inflammation
and myelin loss.4 Disability accumulation independent of
relapses is suggestive of progression,3 mainly due to axo-
nal degeneration.5 Gene–environment interactions are
thought to be involved. A modulating role of the gut
microbiota has been proposed because of its potential to
influence brain development/physiology, regulate immu-
nity,6,7 and increase the odds of murine CNS-specific
autoimmune disease.8,9
Relapsing–remitting (RR)MS patients were repeatedly
shown to have an altered microbiota composition from
healthy controls (HC); however, the identified taxa dif-
fered between studies.9–16 Most studies were small scale
and accounted for few confounders.10,14,16 However, we
recently identified >60 covariates affecting microbial com-
position,17 among which stool consistency had the largest
effect size on primary microbiome markers.17,18 Although
bowel dysfunction is prevalent in MS, this was never con-
trolled for to date.
Controlling for such confounders, we conducted a
cross-sectional study in a cohort of MS patients and HC,
including MS patients with a presumed high (active
RRMS) and low degree of focal CNS inflammation (be-
nign MS (BMS19,20) and nonactive primary progressive
(PP)MS). Subgroups were defined by MS phenotype, dis-
ease course modifiers, and treatment status. We hypothe-
sized to detect a gut microbial community with higher
pro-inflammatory properties in MS subgroups with
higher focal CNS inflammatory activity.
Materials and Methods
Study population
Patients with MS (2010 McDonald criteria21) were
recruited in the National MS Center (NMSC), Melsbroek
(in- and outpatients) and in the University Hospital,
Brussels (outpatients) according to group-specific in- and
exclusion criteria (Table 1). Five MS subgroups were pre-
defined, including three subgroups with a presumed high
degree of focal CNS inflammation: untreated active
RRMS (RRMS_U); untreated RRMS with a relapse at the
time of sampling (RRMS_R); and interferon (IFN) treated
RRMS (RRMS_I). Relapse was defined as new
neurological symptoms lasting ≥24 h, without fever or
other triggers.22 We selected one class of immune-modu-
latory drugs (IMD) to obtain a homogenous treatment
group. IFN-beta was chosen because injectables are
nonaggressive, spare the host’s systemic immunity (less
bias by a direct immune effect on the gut microbiota as
opposed to oral therapy), and limit contact with a hospi-
tal environment (less bias compared to regular visits for
intravenous therapy). The two subgroups with a pre-
sumed low degree of focal CNS inflammation were pro-
gressive onset MS without relapses 2 years prior (PPMS)
and RRMS with ≤3 on the Expanded Disability Status
Scale (EDSS) after a disease duration of ≥15 years
(BMS).19,23 We excluded patients with secondary progres-
sive MS, due to the difficulty to separate inflammation
from neurodegeneration. HC were recruited among par-
ticipants’ proxies, the HC database of the Metabolic
Table 1. In- and exclusion criteria. Untreated groups were untreated
for at least 3 months before inclusion, irrespective of any treatment
before this interval.
Inclusion criteria
Untreated active RRMS (RRMS_U)
At least one clinical relapse during 2 years prior to screening, or at
least one active, contrast-enhancing lesion on brain MRI in the
year prior to screening
EDSS < 7.0
Untreated active RRMS during relapse (RRMS_R)
Able to perform first data collection prior to corticosteroid therapy
EDSS < 7.0
Untreated BMS (BMS)
EDSS ≤ 3.0 at least 15 years after first MS symptoms19,20
IFN treated RRMS (RRMS_I)
At least 3 months of stable treatment with interferon beta
EDSS < 7.0
Non-active PPMS (PPMS)
No clinical relapse within 2 years prior to screening
EDSS < 7.0
Exclusion criteria for MS patients
Secondary progressive MS patients
Disease-modifying treatment other than IFN at screening
Glatiramer acetate treatment within 3 months prior to screening
Fingolimod or natalizumab treatment within 6 months prior to
screening
Systemic corticosteroid use within 2 months prior to screening
Gastrointestinal conditions such as IBD
Antibiotic use in the 4 weeks prior to screening
Exclusion criteria for healthy controls
Systemic corticosteroid use within 2 months prior to screening
Gastrointestinal conditions such as IBD
Other diseases of the central nervous system
Antibiotic use in the 4 weeks prior to screening
Direct relation to or living with a participant in one of the MS
groups
BMS, benign MS; EDSS, expanded disease status scale; IBD, inflamma-
tory bowel disease; IFN, interferon beta; PPMS, primary progressive
MS; RRMS, relapsing–remitting MS.
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Department in the University Hospital Brussels, and
(para)medical staff in the same geographical regions as
MS participants. The HC group was selected to represent
age and sex distributions in the whole MS study popula-
tion. Samples from the Flemish Gut Flora Project
(FGFP17), an independent, large, and diverse population
study on the gut microbiome in Flanders, were added to
this HC group and matched for age, sex, BMI, and the
Bristol Stool Scale (BSS24) against the entire MS popula-
tion. This allowed to project our results on an indepen-
dent and representative sample in the same geographical
area. The ethics committee of the University Hospital,
Brussels, and the local ethics committee of the NMSC,
Melsbroek, approved the study (B.U.N. 143201317985),
which is in compliance with the principles of the 2013
Declaration of Helsinki. All participants provided written
informed consent.
Study design
During study setup, sample size calculation and power
analysis could not be performed because effect size esti-
mates for the gut microbiome were lacking. Following
previous recommendations,25,26 we aimed to include 30
patients per subgroup (and additional FGFP samples for
HC). Potential confounders were assessed following FGFP
protocols,17 covering anthropometrics, general health,
medication, dietary and bowel habits, lifestyle, fertility,
and MS history. Participants noted date and time of stool
sampling, time since last defecation, and scored stool con-
sistency (BSS). Participants were further assessed using
Age-Related Multiple Sclerosis Severity score (ARMSS,27
i.e. age-corrected EDSS ranking), Brief-H-Neg Hopeless-
ness scale,28 Brief Illness Perception Questionnaire (IPQ-
K29; MS only), three-level EuroQol Five Dimensions’
questionnaire (EQ-5D30), Fatigue Scale for Motor and
Cognitive Functions (FSMC), Hospital Anxiety and
Depression Scale (HADS), Hauser Ambulation index
(HAI), and Timed 25 Foot Walk Test (T25FW).
The primary objective was to explore whether gut micro-
biome diversity (alpha and beta), enterotype distribution,
and microbial genus abundances were related to MS diag-
nosis (MS and MS subgroups vs. all HC, respectively) and/
or differences in disease course (MS subgroups). Secondary
objectives were to determine which genera abundances dif-
fered according to IFN treatment (RRMS_U vs. RRMS_I),
and whether certain genera were associated with disease
characteristics and clinical assessments.
Stool sample collection and processing
Fecal collection kits (including instructions following
established protocols17,18) were provided during
consultation. Samples were stored at 20°C immediately
after sampling, in the participants’ home freezer or at the
NMSC, and transferred on dry ice to 80°C within 48 h.
Extraction of microbial DNA from frozen aliquots (150–
200 mg) was performed using an adapted Mobio
PowerMicrobiome DNA/RNA isolation Kit-based proto-
col.17,18 Bacterial DNA was quantified via fluorometry
(Qubit, Life Technologies). The hypervariable 4 region
(V4) of the 16S rRNA gene was PCR amplified (515F/
806R primer set31), with Illumina sequencing adaptors
and dual-index barcodes to generate dual-barcoded
libraries. PCR amplicon quantification was carried out
with Fragment Analyzer (Advanced Analytical Technolo-
gies) and sequencing on the Illumina MiSeq platform
(MiSeq V2 sequencing kit), generating 250 bp paired-end
reads. Following demultiplexing of Illumina sequencing
data, fastq sequences were merged with FLASH software
version (v) 1.2.10.32 Sequences with a quality score <25
(>90% of read length) were excluded from analysis
(FASTX-Toolkit v0.0.14, http://hannonlab.cshl.edu/fa
stx_toolkit/). Chimeric sequences were removed using the
UCHIME algorithm in USEARCH v6.0.307.33 Taxonomi-
cal sequence assignment was performed using the Riboso-
mal Database Project (RDP) classifier v2.12.34 Phylum-to-
genus matrices were created using custom Perl scripts.
Samples were rarefied to 10,000 randomly selected reads.
Statistical analysis
Data analysis was performed in R (v3.3.135). After nor-
mality testing (Shapiro–Wilks test), demographics and
clinical data were compared between groups with one-
way ANOVA or Wilcoxon rank-sum and Kruskal–Wallis
H tests, followed by a post hoc Dunn test (FSA R pack-
age36). Microbiota richness was determined using
observed richness (Sobs; i.e. total number of genera
detected per sample), Pielou’s evenness index (i.e. expres-
sion of how evenly genera are distributed within one sam-
ple), and Simpson’s alpha diversity index (i.e. measure of
alpha diversity including genus richness and evenness)
using vegan37 and phyloseq.38 Group differences were
tested with Wilcoxon rank-sum or Kruskal–Wallis tests
(with post hoc Dunn test). Beta diversity (i.e. difference
in global microbiota composition between samples) was
visualized using Principal Coordinate Analysis (PCoA) on
genus-level community composition (Bray–Curtis dissimi-
larity). The adonis function (vegan) was used to test for
differences in community structure between groups, and
betadisper (vegan) to verify whether differences were due
to dissimilar dispersions among groups. Variables
(N = 732) were filtered by report rate in the study popu-
lation (≥10%). Next, when r > |0.8| using Pearson corre-
lation (Hmisc39), the variable with the lowest effect size
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on genus-level community variation (adjusted R2, vegan’s
capscale) was removed. Variables with the highest effect
sizes in their category were retained. The 33 remaining
metadata variables were used in further analysis. Forward
stepwise distance-based redundancy analysis (RDA, ve-
gan’s ordiR2step) was performed to determine nonredun-
dant microbiome covariates. FGFP individuals were
excluded during RDA and correlation analysis with clini-
cal variables, because not all clinical variables used in this
study were also assessed in the FGFP cohort. In all other
analyses, the FGFP individuals were analyzed alongside
the original HC group, whenever the HC group was
included. Enterotypes were determined with Dirichlet
Multinomial Mixtures (DMM, DirichletMultinomial pack-
age40), using Bayesian Information Criterion (BIC) to cal-
culate the optimal number of clusters.41 To increase
accuracy, enterotyping was performed on a combined
genus abundance matrix that included samples of this
study and 2999 samples from the FGFP.17 Clusters were
named Bacteroides 1 (B1), Bacteroides 2 (B2), Prevotella
(P), and Ruminococcaceae (R) based on enterotype-dis-
criminating predominant taxa.42 B2 has been character-
ized by high Bacteroides and low Faecalibacterium
abundances and lowered cell density.42 Associations
between enterotypes and groups were tested using pair-
wise chi-square tests (chi.sq.post.hoc, fifer package43). Dif-
ferences in relative genera abundances were tested using
Wilcoxon rank-sum and Kruskal–Wallis tests (with post
hoc Dunn test). Genus abundance and correlation analy-
sis were restricted to genera with a mean relative abun-
dance ≥0.0001 (mean ≥ 1 in 10,000 reads) and present in
≥20% of samples. Taxa unclassified at genus level were
excluded. Where appropriate, analyses were corrected for
multiple testing (Benjamini–Hochberg (BH) procedure,44
FDR) resulting in corrected P-values (Pcorr). A false dis-
covery rate (FDR) of <0.1 was considered statistically sig-
nificant. Multivariate analysis was performed using nested
generalized linear models (GLM, glm function). Subgroup
comparisons were controlled for stool consistency (BSS),
age, sex, and BMI. This was not done for the MS versus
HC comparison due to matching at baseline. Adjusted P-
values (Padj) were reported. Standardized regression coef-
ficients were calculated (lm.beta function, QuantPsyc
package45). Associations between genera abundances and
continuous metadata (with removal of HC for MS-speci-
fic scores) were tested using Spearman correlations.
Results
Population
From February 2014 to October 2015, 118 MS patients
and 30 HC were recruited and delivered stool samples. Ta
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Data from 120 participants (98 MS and 22 HC) was
retained for further analysis with 18.9% of samples having
insufficient quality-checked reads. Ninety-eight samples
from the FGFP were added to the HC pool. No signifi-
cant differences were found in age, sex, BMI, and BSS
between overall MS and HC (Table 2). However, age,
EDSS, and disease duration differed among MS sub-
groups. Higher age and EDSS were seen in PPMS com-
pared to RRMS_U (Dunn test, N = 120, Z = 2.74 and
4.86, Pcorr = 0.030 and <0.001) and RRMS_I (Z = 3.16
and 3.44, Pcorr = 0.016 and 0.002), and a higher age
compared to RRMS_R (Z = 2.36, Pcorr = 0.061). BMS
patients had lower EDSS than PPMS and RRMS_I
(Z = 5.56 and 2.25, Pcorr < 0.001 and 0.062), and
longer disease duration than PPMS and RRMS_U
(Z = 2.79 and 4.02, Pcorr = 0.026 and <0.001). RRMS_I
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Figure 1. Boxplot of observed richness within patients (N = 98) and
healthy controls (N = 120, including FGFP samples). Downward trend
of observed richness within the relapsing–remitting patient
population. The body of the boxplot represents the first and third
quartiles of the distribution and median line. The whiskers extend to
the last data point within 1.5 times the interquartile range. The
outliers lie beyond. Individual data points (dots) may overlap. FGFP,
Flemish Gut Flora Project. HC, healthy controls (N = 120). PPMS,
primary progressive multiple sclerosis (N = 26). BMS, benign multiple
sclerosis (N = 20). RRMS_U, untreated active RRMS (N = 24). RRMS_I,
interferon-beta-treated RRMS (N = 24). RRMS_R, RRMS during relapse
(N = 4). Kruskal–Wallis test (N = 218, v2 = 19.24, Pcorr = 0.007) with
post hoc Dunn tests.
Table 3. Differences in observed richness between subgroups. Only
significant results are shown. Reported P-values after Dunn test, with
Benjamini–Hochberg corrected P-values (Kruskal–Wallis test, N = 218,
v2 = 19.24, Pcorr = 0.007).
Comparison N Z-score Pcorr
BMS-RRMS_I 218 3.30 0.015
BMS-RRMS_R 218 2.86 0.021
BMS-HC 218 3.01 0.019
PPMS-RRMS_I 218 2.55 0.040
PPMS-RRMS_R 218 2.40 0.049
PPMS-HC 218 2.09 0.092
HC, healthy controls (N = 120, including FGFP samples); PPMS, primary
progressive multiple sclerosis (N = 26); BMS, benign multiple sclerosis
(N = 20); RRMS_I, interferon-beta-treated RRMS (N = 24); RRMS_R,
RRMS during a relapse (N = 4); P, uncorrected P-value; Pcorr, P-value
corrected for multiple comparisons with Benjamini–Hochberg, FDR.
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Figure 2. Bar plot illustrating the distribution of patient and control
samples (MS vs. HC) over four enterotypes: Prevotella (P, N = 33),
Ruminococcaceae (R, N = 73), Bacteroides 1 (B1, N = 81), and
Bacteroides 2 (B2, N = 31). FGFP, Flemish Gut Flora Project. HC,
healthy controls (N = 120, including FGFP samples). MS, multiple
sclerosis (N = 98). Pearson’s chi-square test for independence,
N = 218, v2 = 36.10, P = 0.002 with pairwise chi-square tests.
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had longer disease duration than RRMS_U (Z = 2.63,
Pcorr = 0.029).
Alpha and beta diversity
Sobs varied greatly within our population (Kruskal–Wallis
test, N = 218, v2 = 19.24, Pcorr = 0.007), with a down-
ward trend from BMS to RRMS_U, RRMS_I, and
RRMS_R (Fig. 1) (Table 3). Simpson’s alpha diversity
index followed a similar trend. A comparison between the
original HC group and the FGFP sample is made in Fig-
ure S1. There were no significant differences in Pielou’s
index between subgroups (Kruskal–Wallis test, N = 218,
Pcorr > 0.5), nor in Sobs, Simpson and Pielou indices
between overall MS and HC (Wilcoxon rank-sum test,
N = 218, Pcorr> 0.5). There were no significant correla-
tions with metadata.
Global microbial composition differed between MS and
HC (adonis test on beta diversity, N = 218, R2adj = 0.004,
P = 0.027), and between subgroups (N = 218,
R2adj = 0.016, P = 0.003). Excluding HC (N = 120), 2.4%
of beta diversity variation was explained by allocation to an
MS subgroup (N = 98, R2adj = 0.024, P = 0.012), largely
driven by RRMS_I (N = 24). Subcutaneous IFN beta-1-a
use (RDA, N = 120, R2adj = 0.024, Pcorr = 0.022), BSS
(R2adj = 0.023, Pcorr = 0.022), subgroup (R2adj = 0.018,
Pcorr = 0.092), weight (R2adj = 0.017, Pcorr = 0.022),
inpatient recruitment (R2adj = 0.014, Pcorr = 0.056),
mobility (25-FWT; R2adj = 0.014, Pcorr = 0.056), sleep
(R2adj = 0.012, Pcorr = 0.056), hopelessness (R2adj =
0.010, Pcorr = 0.090), and EQ-5D (R2adj = 0.009,
Pcorr = 0.092) were identified as covariates of microbiome
variation. BSS had the highest nonredundant effect size on
community variation (2.6%), followed by subcutaneous
IFN beta-1-a use, weight, the first hopelessness question,
daily amount of sleep, and the fifth EQ-5D question.
Enterotypes
Enterotypes were differentially distributed in MS patients
versus HC (Pearson’s chi-square test for independence,
N = 218, v2 = 8.77, P = 0.032), with MS containing the
highest proportion of B2 and lowest proportion of B1
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Figure 3. Bar plot illustrating the distribution of patient and control
samples (comparison between subgroups) over four enterotypes:
Prevotella (P, N = 33), Ruminococcaceae (R, N = 73), Bacteroides 1
(B1, N = 81), and Bacteroides 2 (B2, N = 31). FGFP, Flemish Gut Flora
Project. HC, healthy controls (N = 120, including FGFP samples).
PPMS, primary progressive multiple sclerosis (N = 26). BMS, benign
multiple sclerosis (N = 20). RRMS_U, untreated active RRMS (N = 24).
RRMS_I, interferon-beta-treated RRMS (N = 24). RRMS_R, RRMS
during relapse (N = 4). Pearson’s chi-square test for independence,
N = 218, v2 = 36.10, P = 0.002 with pairwise chi-square tests.
Table 4. Compositional differences between all MS patients and HC.
Only significant results are shown. Reported P-values after Wilcoxon
rank-sum test, with Benjamini–Hochberg corrected P-values (Wilcoxon
rank-sum test, N = 218, Pcorr < 0.1).
Genus N
Effect
size
Median
MS
Median
HC P Pcorr
Alistipes 218 0.18 5.24 4.72 0.007 0.056
Anaerotruncus 218 0.16 0.69 0 0.016 0.080
Butyricicoccus 218 0.24 1.7 2.3 <0.001 0.007
Clostridium
cluster IV
218 0.35 4.14 3.18 <0.001 <0.001
Faecalicoccus 218 0.16 0 0 0.017 0.080
Gemmiger 218 0.30 2.71 3.73 <0.001 <0.001
Intestinibacter 218 0.21 0.69 1.79 0.002 0.029
Lactobacillus 218 0.18 0.69 0 0.009 0.065
Methanobrevibacter 218 0.20 1.61 0 0.004 0.037
Olsenella 218 0.19 0.69 0 0.006 0.049
Parabacteroides 218 0.15 4.56 4.12 0.022 0.097
Roseburia 218 0.17 6.36 6.71 0.014 0.078
Ruminococcus 218 0.17 4.86 4.52 0.014 0.078
Sporobacter 218 0.39 1.61 0.69 <0.001 <0.001
HC, healthy controls (N = 120, including FGFP samples); MS, multiple
sclerosis (N = 98); Effect size (Z/sqrt(N)); Median MS, median abun-
dance of genus (log1p transformed) for MS patients; Median HC,
median abundances of genus (log1p transformed) for HC; P, uncor-
rected P-value; Pcorr, P-value corrected for multiple comparisons with
Benjamini–Hochberg, FDR.
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(Fig. 2); and among clinical subgroups (N = 218,
v2 = 36.10, P = 0.002; Fig. 3). A comparison between the
original HC group and the FGFP sample is made in Fig-
ure S2. B2 had a significantly different subgroup distribu-
tion compared to R and P (Post hoc pairwise chi-square
test, N = 218, v2 = 12.57 and 12.52, Pcorr = 0.047 for
both). Among MS subgroups, most B2-enterotyped
individuals (N = 31) either belonged to RRMS_I (37.5%)
or RRMS_R (18.8%), while P (N = 33) and R (N = 73)
clusters consisted of more BMS (35.7% and 24.3%) and
RRMS_U (42.9% and 24.3%).
Reversely, we found significantly different enterotype
distributions between RRMS_R and RRMS_U and HC
(pairwise chi-square test, N = 218, v2 = 14.73 and 12.47,
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Figure 4. Boxplots illustrating the log1p abundances of Butyricicoccus, Clostridium cluster XVIII, Methanobrevibacter, Parabacteroides, Clostridium
cluster IV, Gemmiger, and Sporobacter genera within the population. Abundances were log1p-transformed for graphic purposes. Individual data
points (dots) may overlap. HC, healthy controls (N = 120, including FGFP samples). PPMS, primary progressive multiple sclerosis (N = 26). BMS,
benign multiple sclerosis (N = 20). RRMS_U, untreated active RRMS (N = 24). RRMS_I, interferon-beta-treated RRMS (N = 24). RRMS_R, RRMS
during relapse (N = 4). Kruskal–Wallis test (N = 218, Pcorr < 0.1) with post hoc Dunn tests.
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Pcorr = 0.031 and 0.045), between HC and PPMS and
BMS (N = 218, v2 = 8.63 and 7.83, Pcorr = 0.097 for
both), between PPMS and RRMS_R (N = 218, v2 = 7.75,
Pcorr = 0.097), between BMS and RRMS_I and RRMS_R
(N = 218, v2 = 8.67 and 9.96, Pcorr = 0.097 and 0.095),
and between RRMS_U and RRMS_I (N = 218, v2 = 8.20,
Pcorr = 0.097). All but one RRMS_R patient had a B2
enterotype. The majority of RRMS_I had B1 (41.67%) or
B2 (25%) enterotypes. Graphics showing the mean genera
distribution within enterotypes as well as genus level hits
per sample per (sub)group are in Figures S3–S10.
Compositional differences
Fourteen microbial genera were differentially abundant
between MS and HC (Wilcoxon rank-sum test, N = 218,
Pcorr < 0.1) (Table 4). Seven were differentially abundant
among subgroups (Kruskal–Wallis test, N = 218,
Pcorr < 0.1) (Fig. 4). Post hoc Dunn test and nested
GLM results are shown in Table 5. The small number of
RRMS_R participants (N = 4) did not allow further sta-
tistical testing. Sporobacter, Clostridium cluster IV, and
Ruminococcus were more abundant in the original HC
group than in the FGFP sample (GLM, N = 120,
Padj < 0.05) (Fig. S11). Median values for the relative
abundances of OTU results in MS and HC groups are
available in Tables S1 and S2.
Correlations with clinical variables
Butyricicoccus abundance inversely correlated with ARMSS
(Spearman correlation test, N = 98, rho = 0.223,
P = 0.027) (Fig. 5), and IPQ-K5 (rho = 0.400,
P = 0.001) (Fig. 6). One male RRMS_U participant with
the shortest time since diagnosis among RRMS partici-
pants had the highest Butyricicoccus abundance. No corre-
lations were found between genera and other clinical
data.
Discussion
No gut microbial diversity measure significantly differed
between MS and HC. However, multiple microbiome
readouts differed between MS subgroups, supporting our
Table 5. Multivariate analysis with nested generalized linear models taking into account Bristol stool score, age, sex, and BMI. Reported effect
sizes and P-values after Dunn and chi-squared tests, with P-values corrected for multiple comparisons with Benjamini–Hochberg.
Genus Comparison N Z-score Dunn Pcorr Dunn SC P Pcorr
Butyricicoccus PPMS–BMS 46 2.56 0.03 1.83 0.020 0.030
PPMS–RRMS_U 50 2.99 0.01 2.94 <0.001 0.003
PPMS–HC 146 4.01 <0.001 2.93 <0.001 <0.001
RRMS_I–BMS 44 2.50 0.03 2.35 0.008 0.012
RRMS_I–RRMS_U 48 2.91 0.01 2.54 0.002 0.004
RRMS_I–HC 144 3.86 <0.001 2.62 <0.001 0.002
Clostridium cluster IV BMS–HC 140 4.32 <0.001 3.26 <0.001 <0.001
PPMS–HC 146 3.33 0.006 1.92 0.002 0.005
RRMS_U–HC 144 3.02 0.012 2.36 <0.001 0.002
Clostridium cluster XVIII RRMS_U–BMS 44 2.11 0.058 1.86 0.023 0.030
RRMS_U–PPMS 50 2.80 0.037 2.01 0.008 0.012
RRMS_U–RRMS_I 48 2.32 0.038 1.57 0.023 0.030
RRMS_U–HC 144 2.82 0.024 2.20 0.004 0.007
Gemmiger BMS–HC 140 2.30 0.081 1.57 0.034 0.041
PPMS–HC 146 2.92 0.027 1.18 0.052 0.057
RRMS_I–HC 144 3.39 0.011 2.14 0.002 0.004
Methanobrevibacter PPMS–RRMS_I 50 2.56 0.078 1.70 0.045 0.051
PPMS–HC 146 3.65 0.004 1.80 0.002 0.005
Parabacteroides RRMS_I–RRMS_U 48 2.00 0.098 0.89 0.236 0.236
RRMS_I–HC 144 2.44 0.004 1.55 0.064 0.067
Sporobacter BMS–HC 140 3.31 0.005 2.29 0.003 0.006
PPMS–HC 146 4.30 <0.001 3.64 <0.001 <0.001
RRMS_I–HC 144 3.75 0.001 3.80 <0.001 <0.001
RRMS_U–HC 144 2.99 0.010 2.21 <0.001 0.002
HC, healthy controls (N = 120, including FGFP samples); PPMS, primary progressive multiple sclerosis (N = 26); BMS, benign multiple sclerosis
(N = 20); RRMS_U, untreated active RRMS (N = 24); RRMS_I, interferon-beta-treated RRMS (N = 24); RRMS_R, RRMS during a relapse (N = 4);
SC, standard coefficient (beta); P, uncorrected P-value; Pcorr, P-value corrected for multiple comparisons with Benjamini–Hochberg, FDR.
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hypothesis of heterogeneity. First, Sobs was inversely
related to the presumed degree of inflammatory disease
activity in MS subgroups: highest in BMS and PPMS and
lowest in RRMS_R. The lower Sobs in RRMS_I might be
explained by the higher amount of CNS inflammation for
which treatment was initiated. At the group level, BMS
and PPMS patients had a higher richness than controls
(including the FGFP sample). That Sobs in HC on average
appears to be in between the Sobs in active (RRMS_I and
RRMS_R) and nonactive MS groups (PPMS and BMS) is
a novel finding,17,18 which cannot be explained by major
confounding factors (e.g. no differences in BSS to account
for constipation). What the higher Sobs in PPMS and
BMS patients when compared with HC exactly means,
remains uncertain. A recent paper warned against basing
health-related conclusions on richness alone, as this could
just be indicative of gut ecosystem age (i.e. the time the
same ecosystem has been in place depending on the tran-
sit time).46 Additionally, approximately 2.4% of interindi-
vidual microbiota compositional variation could be
explained by allocation to a subgroup. Previous MS gut
microbiota studies mainly focused on RRMS,9–16 where
the lack of a common observed signal is probably
explained by the observed intergroup differences and dis-
tinct methodological issues.
Second, a high proportion of MS patients had a B2
enterotype. This was most pronounced in RRMS_I and
RRMS_R patients, which suggests an association with
higher presumed inflammatory activity. However, entero-
type distributions of RRMS_U and BMS were not signifi-
cantly different, even though they differ in inflammatory
disease activity. The relationship between enterotypes and
MS phenotypes, and the interplay between IFN and B2
remain to be elucidated. This is the first time that an
enterotype is associated to (a specific subgroup of) MS.
As this B2 enterotype was associated to Crohn’s disease,42
our results warrant further research on overlapping host–
microbiome interactions in immune-mediated inflamma-
tory diseases.
Third, we observed differences in microbial taxa.
Results for Faecalicoccus,47 Methanobrevibacter,10,13
Ruminococcus,16 and Gemmiger47 confirm previous find-
ings. While Alistipes and Anaerotroncus abundances reflect
findings in a PPMS mouse model,48 we are the first to
find these differentially abundant in RRMS. Not in line
with other studies, Lactobacillus,14 Parabacteroides,14
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Figure 5. Scatterplot illustrating the abundance of Butyricicoccus (log1p-transformed for graphical purposes) according to the ARMSS score of
MS patients. ARMSS, age-related multiple sclerosis severity. PPMS, primary progressive multiple sclerosis (N = 26). BMS, benign multiple sclerosis
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Sporobacter,47 and Clostridium cluster IV13,14 results are
possibly explained by different population subtypes, since
we also included less inflammatory phenotypes, or con-
founder control. Olsenella and Roseburia have been
described as differentially abundant in other inflammatory
conditions.47,49–51
Butyricicoccus abundance was lower in MS than in
the total HC group, as confirmed in a previous
paper.47 Between-group analysis suggests an inverse rela-
tionship between Butyricicoccus abundance and pre-
sumed CNS inflammation in RRMS. Lower
Butyricicoccus abundance in PPMS might be explained
by the less prominent role of focal inflammatory dis-
ease activity. Butyricicoccus is a spore-forming genus
from the Clostridium cluster IV known to produce
short-chain fatty acids,52 which can initiate anti-inflam-
matory effects through regulatory T-cell induction.53
Through this mechanism the gut microbiota might con-
tribute to MS pathogenesis.54,55 Butyricicoccus and
Clostridium cluster XVIII have never before been found
differentially abundant within MS.9–16 While lower
abundances of certain Clostridium cluster IV species
have been reported, none were of the type known to
induce regulatory T-cells.15 In line with our results,
Butyricicoccus pullicaecorum was shown less abundant in
IBD patients than in HC.50 Lastly, Butyricicoccus abun-
dance was inversely correlated with age-corrected disease
burden and self-reported disability. Given also the fact
that Butyricicoccus was found to be well tolerated for
human administration,56 these results highlight Butyrici-
coccus as a promising novel target in MS.
Strengths
Including MS subgroups with well-defined disease charac-
teristics and disease course modifiers enabled us to evalu-
ate the gut microbiome in terms of higher or lower
degree of presumed focal CNS inflammation. Restricting
treatment to IFN-beta allowed studying the gut micro-
biome in a homogenous treatment group. The RRMS_U
group permitted to investigate the gut microbiome in MS
without treatment effects. We controlled for the effect of
constipation through BSS and other covariates known to
affect gut microbial composition.18
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Figure 6. Scatterplot illustrating the abundance of Butyricicoccus according to the degree of physical symptoms patients report in the fifth
question of the brief illness perception questionnaire (IPQ-K5: 0 = none, 10 = multiple and serious symptoms). The outlier is explained in text.
PPMS, primary progressive multiple sclerosis (N = 26). BMS, benign multiple sclerosis (N = 20). RRMS_U, untreated active RRMS (N = 24). RRMS_I,
interferon-beta-treated RRMS (N = 24). RRMS_R, RRMS during relapse (N = 4). Spearman correlation test, N = 98, rho = 0.400, Pcorr = 0.001.
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Limitations
First, categorization bypasses the natural spectrum of a
heterogeneous disease, which may have resulted in errors
of classification. Second, without MRI data on subclinical
disease activity, the degree of focal inflammation may be
underestimated in all groups. Third, despite attempts to
increase the size of RRMS_R (N = 4), reported differ-
ences require replication in larger, independent study
groups. Fourth, it is unclear whether microbial differences
between the original HC and FGFP samples reflect natural
diversity or sampling bias.
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Figure S1. Boxplot of observed richness within the origi-
nal healthy control samples (N = 22) and those from the
FGFP (N = 98). The body of the boxplot represents the
first and third quartiles of the distribution and median
line. The whiskers extend to the last data point within 1.5
times the interquartile range. The outliers lie beyond.
Individual data points (dots) may overlap. HC_FGFP,
healthy controls from the Flemish Gut Flora Project.
HC_MICR, original healthy control sample.
Figure S2. Bar plot illustrating the distribution of four
enterotypes within the original healthy control samples
and those from the FGFP, Prevotella (P), Ruminococ-
caceae (R), Bacteroides 1 (B1), and Bacteroides 2 (B2).
HC_FGFP, healthy controls from the Flemish Gut Flora
Project. HC_MICR, original healthy control sample.
Figure S3. Barplot showing the distribution of main dis-
criminating genera in enterotypes in the whole study pop-
ulation (N = 218). Other genera are combined in
“Remainder.” The y-axis shows the proportional abun-
dance per sample.
Figure S4. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the healthy control group from the Flemish Gut Flora
Project (HC_FGFP, N = 98). Other genera are combined
in “Remainder.” The y-axis shows the proportional abun-
dance per sample. OTU, operational taxonomic unit.
Figure S5. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the original healthy control group (HC_MICR, N = 22).
Other genera are combined in “Remainder.” The y-axis
shows the proportional abundance per sample. OTU,
operational taxonomic unit.
Figure S6. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the benign MS group (BMS, N = 20). Other genera are
combined in “Remainder.” The y-axis shows the propor-
tional abundance per sample. OTU, operational taxo-
nomic unit.
Figure S7. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the untreated active relapsing–remitting MS group
(RRMS_U, N = 24). Other genera are combined in
“Remainder.” The y-axis shows the proportional abun-
dance per sample. OTU, operational taxonomic unit.
Figure S8. Barplot showing the distribution of the 61 most
prevalent genera in samples from each subject in the active
relapsing–remitting MS group treated with interferon beta
(RRMS_I, N = 24). Other genera are combined in
“Remainder.” The y-axis shows the proportional abun-
dance per sample. OTU, operational taxonomic unit.
Figure S9. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the active relapsing–remitting MS group recruited during
a relapse (RRMS_R, N = 4). Other genera are combined
in “Remainder.” The y-axis shows the proportional abun-
dance per sample. OTU, operational taxonomic unit.
Figure S10. Barplot showing the distribution of the 61
most prevalent genera in samples from each subject in
the non-active primary progressive MS group (PPMS,
N = 26). Other genera are combined in “Remainder.”
The y-axis shows the proportional abundance per sample.
OTU, operational taxonomic unit.
Figure S11. Boxplots illustrating the log1p abundances of
genera Bifidobacterium, Clostridium cluster IV, Clostridium
cluster XIVa, Fusicatenibacter, Romboutsia, Ruminococcus,
Sporobacter, Terrisporobacter, and Turicibacter within the
healthy control population. Abundances were log1p-trans-
formed for graphic purposes. Individual data points
(dots) may overlap. HC_FGFP, healthy controls from the
Flemish Gut Flora Project. HC_MICR, original healthy
control sample. Kruskal–Wallis test (N = 120,
Pcorr < 0.1) with post hoc Dunn tests.
Table S1. Relative abundance of bacterial genera found
per MS subgroup (expressed per 10.000 reads). Taxa
unclassified at genus level, genera with a mean relative
abundance <1 in 10,000 reads and present in <20% of all
418 © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
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samples were excluded. Median values are shown. The
proportion (%) of samples per group containing the
genus is mentioned between brackets.
Table S2. Relative abundance of bacterial genera found
per healthy control group (expressed per 10,000 reads).
Taxa unclassified at genus level, genera with a mean rela-
tive abundance <1 in 10,000 reads and present in <20%
of all samples were excluded. Median values are shown.
The proportion (%) of samples per group containing the
genus is mentioned between brackets.
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